You are here

Oncology Pipeline

Novel therapies, new mechanisms

Pfizer Oncology is committed to discovering, investigating, and developing transformative therapies that improve the outlook for cancer patients worldwide.

Our strong pipeline—one of the most robust in the industry—includes biologics, small molecules, immunotherapies, and biosimilars, and is centered on exploring a wide array of approaches across many tumor types. We seek to translate the most innovative science into meaningful breakthrough medicines that redefine life with cancer for patients.

 

Oncology Pipeline Snapshot as of August 1, 2017

  • Discovery Projects
  • Phase 1
    13
  • Phase 2
    5
  • Phase 3
    20
  • Registration
    4
  • Total42
 
Compound Name
Indication
Phasesort descending
Submission Type
Compound Type
lorlatinib (PF-06463922)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
ALK Inhibitor
Go to clinical trial
1st Line ALK Non-Small Cell Lung Cancer (ORPHAN - U.S.) Phase 3 Product Enhancement Small Molecule
talazoparib (MDV3800)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
PARP inhibitor
Go to clinical trial
Germline BRCA Mutated Metastatic Breast Cancer Phase 3 New Molecular Entity Small Molecule
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Anti PD-L1 Inhibitor
Go to clinical trial
2nd Line Metastatic Merkel Cell Carcinoma (E.U.) (Biologic) Registration New Molecular Entity Biologic
inotuzumab ozogamicin
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
CD22-targeted cytotoxic agent
Go to clinical trial
Acute Lymphoblastic Leukemia (U.S.) (Biologic) (BREAKTHROUGH, PRIORITY REVIEW, ORPHAN) Registration New Molecular Entity Biologic
Mylotarg
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
CD33-targeted cytotoxic agent
Go to clinical trial
1st Line Acute Myeloid Leukemia (Biologic) Registration Product Enhancement Biologic
Sutent (sunitinib)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Multiple Tyrosine Kinase Inhibitor
Go to clinical trial
Renal Cell Carcinoma Adjuvant
Project advanced
Registration Product Enhancement Small Molecule
  •